Exhibit (a)(1)(D)
Offer to Purchase for Cash
All Outstanding Shares of Common Stock
of
DIPLOMAT PHARMACY, INC.
at
$4.00 per share, net in cash,
pursuant to the Offer to Purchase dated January 9, 2020
by
DENALI MERGER SUB, INC.
a direct wholly owned subsidiary of
UNITEDHEALTH GROUP INCORPORATED
THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:01 A.M., NEW YORK CITY TIME,
ON FEBRUARY 7, 2020, UNLESS EXTENDED OR EARLIER TERMINATED.
January 9, 2020
To Brokers, Dealers, Commercial Banks, Trust Companies and other Nominees:
Denali Merger Sub, Inc., a Michigan corporation (“Purchaser”) and a direct wholly owned subsidiary of UnitedHealth Group Incorporated, a Delaware corporation (“UnitedHealth Group”), and UnitedHealth Group have appointed D.F. King & Co., Inc. to act as the information agent (the “Information Agent”) in connection with Purchaser’s offer to purchase all outstanding shares (the “Shares”) of common stock, no par value (the “Common Stock”), of Diplomat Pharmacy, Inc., a Michigan corporation (“Diplomat”), at a price of $4.00 per Share, net to the seller in cash (the “Offer Price”), without interest and subject to any required tax withholding, on the terms and subject to the conditions described in the Offer to Purchase, dated January 9, 2020 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), the accompanying Letter of Transmittal (as it may be amended or supplemented from time to time, the “Letter of Transmittal”) and other related materials (which, together with the Offer to Purchase and the Letter of Transmittal, collectively constitute the “Offer”), all of which are enclosed herewith.
Please furnish copies of the enclosed materials to those of your clients for whom you hold Shares registered in your name or in the name of your nominee.
THE BOARD OF DIRECTORS OF DIPLOMAT HAS UNANIMOUSLY RECOMMENDED THAT THE SHAREHOLDERS OF DIPLOMAT ACCEPT THE OFFER AND TENDER THEIR SHARES TO PURCHASER IN THE OFFER.
The conditions of the Offer are described in Section 14 of the Offer to Purchase.
For your information and for forwarding to your clients for whom you hold Shares registered in your name or in the name of your nominee, enclosed herewith are copies of the following documents:
| 1. | Offer to Purchase, dated January 9, 2020; |
| 2. | Letter of Transmittal for your use in accepting the Offer and tendering Shares and for the information of your clients, including the FormW-9; |